No Detail Found!

Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia

Author(s)
May AlMoshary Basic Science Department, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Shatha Mahmoud Altahan Department of Pathology and Clinical Laboratory Medicine, Administration, King Fahad Medical City, Saudi Arabia.
Aziza Fayed Alswayyed Department of Pathology and Clinical Laboratory Medicine, Administration, King Fahad Medical City, Saudi Arabia.
Abstract
Objectives: To evaluate the outcomes (relapse and mortality rate) and response of the bone marrow in early stages after combination chemotherapy in patients with T-cell Acute Lymphoblastic Leukemia (T-ALL). Methods: A descriptive cross-sectional study was conducted at King Fahad Medical City, from January 2021 to December 2022, to evaluate bone marrow findings at the time of diagnosis and post-chemotherapy in 26 patients diagnosed with T-ALL. The study included all patients diagnosed with T-ALL of any age group during the study period. The patients' bone marrows were examined at 0 days of treatment (diagnosis work-up), followed by examination at day 15 post induction therapy, and day 30 after treatment. Results: In this study, 26 cases of T-lymphoblastic leukemia were analyzed. The mean age at diagnosis was 15.69±14.28 years, and eight cases had central nervous system involvement. The majority of cases (88.5%) were positive for Cytoplasmic-CD3 and CD7. Positive findings by fluorescence in situ hybridization (FISH) were: T cell receptor (TCR) a/d in 6 (23.1%) of the patients, CDNK2A/CEP9 in five (19.2%), and TRCB in one (3.8%). Examination of the bone marrow on day 15 revealed a decrease in blasts to =1% in nine patients, and to =1% in 19 patients on day 30 post-therapy. Relapse was recorded in five (19.23%) patients. Three (11.53%) patients did not survive during treatment, of which two were <10 years old. The relapse rate for T-ALL was 19.23%, with an overall survival rate of about 64%. The overall mortality rate was 11.53%. Conclusion: The relapse rate for T-ALL in our study was approximately 19%, but the mortality rate was 11.5%. A substantial decrease in blast percentages was observed, suggesting a favorable initial reaction of the bone marrow to the combined chemotherapy. This suggests that the use of aggressive and more efective chemotherapy has led to better outcomes.
Publication Details
Page(s) 979-984
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
Cancer, Relapse, bone marrow, Leukemia, Outcomes, T-ALL
0

Citations

0

Downloads

79

Views